<ul data-eligibleForWebStory="true"><li>Lamark Biotech, a biopharma startup, secured Rs 6.5 crore in pre-Series A funding from IAN Group and other investors.</li><li>Founded in 2018 by Dr. Vaibhav Bhatia, the company specializes in drug delivery for chronic diseases using its ProteoStrong platform.</li><li>Lamark's focus is on stabilizing protein-based drugs like insulin without altering their structure, addressing the biologics ecosystem's cold-chain dependency issue.</li><li>The startup plans to expand its thermostable biologics globally, targeting markets like India and Southeast Asia, aiming to file new patents and start clinical trials in the next 24 months.</li></ul>

Innovation-led biopharma startup Lamark Biotech raises Rs 6.5 crore in funding

Discover more